{"id":"fluarix-tm","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluarix contains inactivated (killed) influenza virus antigens from three or four seasonal flu strains. When administered, it triggers the adaptive immune response, prompting B cells to produce neutralizing antibodies and T cells to develop cellular immunity against the included influenza strains. This immune priming protects vaccinated individuals from infection or reduces disease severity if exposure occurs.","oneSentence":"Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:59.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT05447078","phase":"PHASE3","title":"Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2022-07-01","conditions":"Healthy Volunteers","enrollment":492},{"nctId":"NCT04978454","phase":"PHASE1","title":"Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":"Influenza","enrollment":60},{"nctId":"NCT06614361","phase":"PHASE2","title":"Community-based Behavioral Intervention to Increase Vaccination Using MOST","status":"WITHDRAWN","sponsor":"New York University","startDate":"2025-04-01","conditions":"COVID 19, Influenza","enrollment":""},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT00753272","phase":"PHASE3","title":"Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-15","conditions":"Influenza","enrollment":43695},{"nctId":"NCT00321763","phase":"PHASE2","title":"Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-27","conditions":"Influenza","enrollment":3124},{"nctId":"NCT01160237","phase":"PHASE3","title":"Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Influenza","enrollment":7},{"nctId":"NCT00851266","phase":"PHASE1","title":"A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Influenza","enrollment":187},{"nctId":"NCT01199861","phase":"PHASE3","title":"Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Relapsing Multiple Sclerosis","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluarix TM","genericName":"Fluarix TM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}